NCCN Guidelines® Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of BTKi and BCL-2 inhibitors as a preferred treatment approach for treatment-naive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has significantly transformed the treatment landscape of relapsed/refractory disease. The benefit/risk of continuous vs fixed duration treatment should be carefully evaluated. Sequencing of therapy, when done appropriately, can potentially improve response rates and treatment tolerance in patients with previously treated CLL/SLL. Careful monitoring of adverse events after initiation of treatment and supportive care for the treatment related complications should be an integral part of CLL/SLL management. Informing clinicians about the recent updates to NCCN Guidelines for CLL/SLL should help clinicians integrate the treatment options more effectively into their clinical decision making.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this program, participants should be able to:
- Review the current treatment options for patients with newly-diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Discuss the available evidence on sequencing therapy for patients with previously treated CLL/SLL.
- Individualize treatment plans integrating recommendations outlined in the NCCN Guidelines for the management for patients with newly diagnosed and relapsed/refractory CLL/SLL.
Deborah M. Stephens, DO
Huntsman Cancer Institute at the University of Utah
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
Deborah M. Stephens, DO
AbbVie, Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee BeiGene: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee Celgene Corporation: Consulting Fee
Eli Lilly and Company: Consulting Fee Genentech, Inc.: Consulting Fee
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Matt Kalaycio, MD
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Johnson & Johnson: Equity Interest/Stock Options
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-23-056-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 ANCC Pharmacology Contact Hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing